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Aims Brugada syndrome (BrS) is an inherited channelopathy that predisposes to malignant ventricular arrhythmias and
thereby syncope and sudden cardiac death. Prior studies characterizing BrS patients have used highly selected referral
populations from tertiary centres and prevalence estimates have been carried out using electrocardiogram (ECG)
surveys only. We aimed to identify and characterize all diagnosed BrS patients in Denmark (population 5.4 million).
Methods
and results
Brugada syndrome patients were identified using several modalities including identification in all Danish tertiary re-
ferral centres, search in public health registries, contact to all cardiology departments in Denmark, and searching in a
pedigree database for inherited heart disease used nationwide in Denmark. We identified 43 definite diagnosed BrS
patients and 25 possible BrS patients, corresponding to a prevalence of 1.1 definite BrS cases per 100 000 inhabitants.
Most definite BrS patients were men (86%) and the median age at diagnosis was 48 years. A total of 35 definite BrS
patients (81%) had an implantable cardioverter defibrillator (ICD) implanted and of these 9 (26%) experienced ap-
propriate shocks and 3 (8%) experienced inappropriate shocks during a median follow-up of 47 months. No patient
died or experienced aborted sudden cardiac death during follow-up.
Conclusions We report the first nationwide study of BrS patients. We found a low incidence of diagnosed definite BrS compared
with estimates from ECG surveys. Follow-up data show a lower rate of inappropriate therapies in ICD carriers than
that reported in previous studies.
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Introduction
Brugada syndrome (BrS) (OMIM ID 601144) is a primary arrhyth-
mia syndrome characterized by the occurrence of malignant ven-
tricular arrhythmias often during rest or sleep and characteristic
electrocardiogram (ECG) changes in the right precordial leads
(V1–V3).1 Brugada syndrome patients are typically males diag-
nosed in their 40s and many are and seem to remain asymptomatic
during follow-up.2–4 Brugada syndrome is regarded as an
autosomal-dominant disorder, although many cases seem to be
sporadic.2 Brugada syndrome was first described as a separate
entity in 1992,5 and has since been associated with mutations
affecting mainly the cardiac sodium (Ina) current but also the
calcium (ICaL) and potassium (Ito) currents.
6–9 However, some of
the associations with regard to the calcium and potassium currents
are based on single-mutation findings in families with weak
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genotype phenotype co-segregation and may thus be false associa-
tions.10 Furthermore in only 20–30% of cases a likely genetic cause
is found.
In general, two kinds of epidemiologic studies have been carried
out in the field of BrS: (i) studies trying to estimate the population
prevalence and (ii) studies trying to characterize the prognosis and
risk factors in BrS patients.
The first type of studies typically uses ECGs from population
studies,11 or from screening efforts,12 and BrS patterns are identi-
fied from the ECGs. These studies thereby aim to estimate the
population prevalence of BrS using the ECG pattern as a proxy.
However, the diagnosis of BrS requires more than just a BrS
type 1 ECG pattern,1 and the studies suffer from not being able
to identify BrS but only BrS type 1 ECG patterns, resulting in
low specificity. Furthermore, as the presence of a type 1 ECG
pattern fluctuates significantly over time even in definitely diag-
nosed BrS patients they also suffer from reduced sensitivity.13
The second type of studies has mainly included patients from ter-
tiary centres and covered ‘opportunistic’ geographical areas. This
could lead to bias in the form of mainly including very symptomatic
and/or resourceful patients, as both these categories of patients
are more likely to be referred to tertiary centres.
We aimed to do a nationwide study of BrS patients using four
different modalities to identify all diagnosed patients in Denmark
(population 5.4 million) and characterize the population.
Methods
Identification of subjects
Different modalities were used in the attempt to identify all diagnosed
BrS patients in Denmark: (i) all tertiary referral centres (n ¼ 5) parti-
cipated in this study and identified all their BrS patients; (ii) a letter
was sent to all cardiology departments in Denmark asking them to
report any BrS patients; (iii) a search for international classification
of diseases (ICD)-10 codes DI472L (Brugada ECG pattern, unspeci-
fied), DI472LA (Brugada ECG pattern, type 1), DI472LB (Brugada
ECG pattern, type 2), DI472LC (Brugada ECG pattern, type 3), and
DI472M (Brugada syndrome) was conducted in the Danish National
Patient Registry, a registry with complete nationwide coverage,
covering all hospital visits with ICD-10 diagnostic codes since 1994;
and (iv) a search was conducted in a nationwide database used by all
the tertiary referral centres in Denmark for recording pedigree data
for families with inherited heart diseases (Progeny Clinical, Progeny
Software LLC, USA).
Collection of data
Data were entered into an online web-based registry. All data were
validated by one of the authors (A.G.H.) by reviewing the original
patient records. Data on ICD therapies were validated by going
through the ICD records for all patients with an ICD.
Definitions
The presence of BrS type 1–3 ECG patterns was defined as noted in
the second BrS consensus report.1 Patients were divided into definite
and possible BrS patients. Definite BrS patients were patients fulfilling
the diagnostic criteria according to the consensus report.1 Possible BrS
patients were patients with a BrS type 1 ECG pattern but without ful-
filling other diagnostic criteria.
Date of diagnosis was defined as the date on which a definite diag-
nosis of BrS was established.
Statistical analyses
Values were reported as mean (standard deviation) when normally dis-
tributed and median [interquartile range (IQR)] when not. Differences
between groups were tested using Student’s t-test for continuous vari-
ables. All analyses were done using Stata 11 (StataCorp LP).
The study was approved by the Danish Data Protection Agency.
Results
Identification
Sixty-two patients were primarily identified through tertiary
centres, four additional patients were identified through the
Danish National Patient Registry, two additional patients (both of
them family members) were identified through the nationwide
pedigree database, and finally no additional patients were identified
through the contact to all cardiology departments (all had been
referred to tertiary centres).
Characteristics
Follow-up and inclusion ended on 1 June 2011. A total of 43 def-
inite BrS patients and 25 possible BrS patients were identified.
Characteristics for the group of BrS patients are shown in
Table 1. Most definite BrS patients were men (86%) and the
median age at diagnosis was 48 years (see Figure 1). No patient
died or experienced aborted sudden cardiac death (ASCD)
during follow-up, but 26% experienced ASCD before baseline.
Prevalence
We identified 43 definite BrS patients in Denmark and with a
population of 4 056 152 in the corresponding age group (21–82
years) this translates into a prevalence of 1.1 per 100 000.
Electrocardiogram parameters
Electrocardiogram parameters divided into groups with and
without SCN5A mutation are shown in Table 2. The group with
SCN5A mutation was found to have a significantly prolonged PR
interval (P ¼ 0.01) on the ECG compared with the group
without SCN5A mutation.
Medication
Only one patient was treated medically for recurrent ventricular
tachycardia or fibrillation. The patient experienced .20 episodes
of ventricular fibrillation over a period of 18 months. All epi-
sodes were terminated by ICD shocks. After initiation of quinidine
shocks to reduce the number of ICD shocks, 2 years have passed
without any arrhythmias.
Electrophysiological study and
implantable cardioverter defibrillator
A total of 25 definite BrS patients underwent electrophysiological
study (EPS) and of these, 19 were inducible to either sustained
poly- or monomorphic ventricular tachycardia or ventricular fibril-
lation. Data on ICD shocks are shown in Table 3. A total of 35
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definite BrS patients had an ICD implanted and of these 9 (26%)
experienced appropriate shocks and 3 (8%) experienced inappro-
priate shocks during follow-up. No patient experienced both ap-
propriate and inappropriate shocks.
Discussion
We report the first nationwide study of diagnosed Brugada
patients. Other studies of BrS populations have mainly enrolled
patients from tertiary centres, thus being sensitive for referral bias.
We found a prevalence of definite BrS of 1.1 per 100 000
persons. As noted in the introduction other studies have tried to
estimate the prevalence of BrS by identifying ECGs with BrS
patterns. When looking at studies performed in populations of
mainly European ethnicity a recent study using data from the Co-
penhagen City Heart Study reviewed 42 560 ECGs from 18 974
participants and found that no ECGs are exhibiting a type 1
pattern.11 Another study using data from the German KORA
study studied 4149 participants and also found no type 1 pat-
terns.14 Other surveys found 2 out of 12 012 (Italy),15 1 out of
1000 (France),16 and finally 2 out of 11 488 (Greece) participants
with a type 1 pattern.17 This corresponds to a prevalence of 10 per
100 000 persons with type 1 ECG patterns in these European
populations and is 10 times higher than our prevalence of diag-
nosed BrS cases. Multiple explanations are likely for this discrep-
ancy: First and foremost a type 1 pattern is not enough to meet
the BrS diagnostic criteria, and it is well established that many
patients with a type 1 pattern remain asymptomatic and are
without family history of sudden death.2–4,12 The only way that
these patients can become definite BrS patients is to demonstrate
inducibility during EPS, something that is not done routinely in
most Danish centres. Secondly, maybe the true prevalence rate
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Clinical characteristics for Danish Brugada
syndrome patients
Definite
patients
Possible
patients
Cases, n 43 25
Probands, n 33 22
Male gender 37 (86%) 16 (64%)
Median age (IQR), years 52 (36–62) 47 (39–58)
Median age at diagnosis (IQR), years 48 (32–61) –
Median follow-up time (IQR), months 43 (14–83) 35 (9–52)
Reason for initial contact
Aborted sudden death 10 (23%) 4 (16%)
Chest pain (typical and atypical) 5 (12%) 6 (24%)
Syncope 10 (23%) 2 (8%)
Near syncope 2 (5%) 2 (8%)
Palpitations 2 (5%) 4 (16%)
Family examination 11 (26%) 3 (12%)
Other 3 (7%) 4 (16%)
Spontaneous ECG pattern
Type 1 29 (67%) 13 (52%)
Type 2 3 (7%) 3 (12%)
Type 3 7 (16%) 7 (28%)
Not Brugada 4 (9%) 2 (8%)
Provoked type 1 ECG pattern 20 (47%) 5 (20%)
EPS result
Not tested 18 (42%) 19 (76%)
Not inducible 6 (14%) 2 (8%)
Ventricular tachycardia 8 (19%) 2 (8%)
Ventricular fibrillation 11 (26%) 2 (8%)
Pre-baseline syncope 19 (44%) 3 (12%)
Pre-baseline ASCD 11 (26%) 4 (16%)
Nocturnal agonal respiration 6 (14%) 0 (0%)
Atrial fibrillation, n 8 (19%) 3 (12%)
Family history/genetics (probands only)
Familial type 1 ECG, n 4 (12%) 2 (9%)
Familial sudden death ,45 years, n 3 (9%) 1 (5%)
Familial SIDS, n 0 (0%) 0 (0%)
SCN5A mutation, positive/tested 7/27 (26%) 0/0 (0%)
Data reported as n (%) unless otherwise indicated. IQR, interquartile range.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Electrocardiogram parameters in Danish
definite Brugada syndrome patients with and without
SCN5A mutation
Parameter All
patients
(n 5 44)
SCN5A
mutation
(n 5 7)
No SCN5A
mutation
(n5 17)
P value
PR interval, ms 191 (35) 225 (46) 178 (19) 0.01
QRS duration,
ms
113 (19) 127 (27) 110 (15) 0.09
Max ST-
elevation,
mV
4.5 (2.9) 3.3 (3.3) 4.8 (2.4) 0.07
Data reported as mean (standard deviation). P values derived from testing for
differences between groups with and without SCN5A mutation.
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Figure 1 Age at diagnosis for definite Brugada syndrome
patients in Denmark.
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of type 1 patterns in the Danish population is much lower than 10
per 100 000. This is supported by the aforementioned ECG
surveys performed in Denmark and Germany, which found no
type 1 patterns, maybe reflecting a true difference in prevalence
between northern and southern Europe. The often-cited preva-
lence in the range of 50 per 100 000 persons1,18 is thus maybe a
gross overestimation of the true prevalence of definite BrS at
least in northern Europe.
We found 25 possible BrS cases, but this was a very heterogen-
ous group and, as can be seen from Table 1, not all of them dis-
played the type 1 ECG pattern either spontaneously or during
provocation testing. As such, this group probably encompasses
other phenotypes as well, and will not be discussed further.
The demographics of our definite population were comparable
with what was found in the FINGER registry with 86 vs. 72% men
and a median age at diagnosis of 52 vs. 45 years, respectively.2 We
also found comparable rates of SCN5A mutations carriers when
compared with the FINGER registry (26 vs. 22%),2 and we found
the PR interval to be significantly prolonged in SCN5A mutation
carriers as reported previously.19–21
With regard to ICD therapies we found that during a median
follow-up of 47 months 26% of ICD recipients received appropri-
ate shocks and only 8% received inappropriate shocks. Sacher
et al.22 studied 220 BrS ICD patients with a mean follow-up of
38 months and found that 8% received appropriate and 20%
received inappropriate shocks. Sarkozy et al.4 studied 47 patients
during a median follow-up of 48 months and found that 15%
received appropriate and 36% received inappropriate shocks.
Rosso et al.23 studied 59 patients and during a mean follow-up of
45 months found that 8% received appropriate and 27% received
inappropriate shocks. Our ratio between appropriate and inappro-
priate shocks thereby differs significantly from others. This could
be due to a different severity of disease in our ICD population
compared to others. As such we found a high proportion of
ICD carriers with a spontaneous type 1 pattern (74%), syncope
(46%), and ASCD (26%), the three only factors that have been
consistently associated with a poor prognosis in multivariate ana-
lyses.2,24,25 Sacher et al. found a lower proportion of ASCD
(8%), comparable proportion of syncope (40%) and type 1 ECG
(62%). Sarkozy et al. excluded cases with ASCD, and found a
lower proportion of type 1 ECGs (49%) and syncope (55%).
Rosso et al. found a somewhat lower proportion of ASCD
(18%) and comparable proportions of syncope (53%) and type 1
ECG (63%). Thus, some of the differences with regard to ICD
shocks can be explained by disease severity differences between
the studies, but most must stem from other factors such as
better discrimination algorithms in newer ICDs as well as better
programming of these. An alternative explanation could be avoid-
ance of triggers such as certain drugs (www.brugadadrugs.org) or
treatment of fever.26
Although the rate of inappropriate therapies was low, a signifi-
cant number (14%) of patients underwent lead replacements, indi-
cating that the overall ICD complication rate in this population was
still fairly high.
Of note no deaths occurred, either in ICD carriers or in non-
carriers during follow-up, indicating good risk stratification.
Limitations
Our study design has some clear limitations. First and foremost we
only identified diagnosed BrS patients and a large number of indi-
viduals with BrS, without doubt, remain undiagnosed, in some of
the cases the first symptom being sudden cardiac death/aborted
cardiac arrest, as recently shown by Raju et al.27 Our group has re-
cently found an incidence rate of sudden unexplained death
(sudden death with a negative autopsy) in the young (aged 1–35
years) in Denmark of 0.8 per 100 000 person-years.28 Studies
examining the diagnostic yield of screening relatives to victims of
sudden unexplained death find that 9–15% of cases, on the basis
of findings in relatives, is assumed to be due to BrS.29,30 This
implies that each year up to five cases of sudden unexplained
death in Denmark could be due to undiagnosed BrS.
Secondly, we cannot exclude the possibility that we have missed
even some diagnosed BrS patients. But as the health care system in
Denmark (a public single-payer system) is highly integrated, homo-
genous and health care data are universally accessible we believe
we were able to identify most if not all patients.
Unfortunately, we had no data on ICD complications such as in-
fection and pneumothorax and thus could not report this.
Conclusions
In conclusion, we report the first nationwide study of diagnosed
BrS patients. We found a low incidence of diagnosed definite
BrS compared with estimates from European ECG surveys. Follow-
up data show a lower rate of inappropriate therapies in ICD reci-
pients than previous studies.
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Table 3 Characteristics and follow-up data for Danish
definite Brugada syndrome patients with implantable
cardioverter defibrillator
Patients with ICD 35
Median FU time with ICD (IQR), months 47 (14–94)
Risk factor in ICD patients
ASCD 9 (26%)
Syncope 16 (46%)
Spontaneous type 1 ECG pattern 26 (74%)
ICD events
Appropriate shocks, patients 9 (26%)
Inappropriate shocks, patients 3 (8%)
Lead change, patients 5 (14%)
Battery change, patients 8 (23%)
Data reported as n (%) unless otherwise indicated. ICD, implantable cardioverter
defibrillator; FU, follow-up.
A.G. Holst et al.1028
by guest on January 16, 2017
D
ow
nloaded from
 
References
1. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D et al.
Brugada syndrome: report of the second consensus conference: endorsed
by the Heart Rhythm Society and the European Heart Rhythm Association.
Circulation 2005;111:659–70.
2. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL et al. Long-term
prognosis of patients diagnosed with Brugada syndrome: results from the FINGER
Brugada syndrome registry. Circulation 2010;121:635–43.
3. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-
term follow-up of individuals with the electrocardiographic pattern of right
bundle-branch block and st-segment elevation in precordial leads V1 to V3.
Circulation 2002;105:73–8.
4. Sarkozy A, Boussy T, Kourgiannides G, Chierchia G-B, Richter S, De Potter T
et al. Long-term follow-up of primary prophylactic implantable cardioverter-
defibrillator therapy in Brugada syndrome. Eur Heart J 2007;28:334–44.
5. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation
and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A
multicenter report. J Am Coll Cardiol 1992;20:1391–6.
6. Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A et al. A Mu-
tation in the {beta}3 subunit of the cardiac sodium channel associated with
Brugada ECG phenotype. Circ Cardiovasc Genet 2009;2:270–8.
7. Antzelevitch C. Genetic basis of Brugada syndrome. Heart Rhythm 2007;4:756–7.
8. Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpo´n E, Hu D, Desai M et al.
Mutations in the cardiac L-type calcium channel associated with inherited j
wave syndromes and sudden cardiac death. Heart Rhythm 2010;7:1872–82.
9. Giudicessi JR, Ye D, Tester DJ, Crotti L, Mugione A, Nesterenko VV et al. Tran-
sient outward current (Ito) gain-of-function mutations in the KCND3-encoded
Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 2011;8:1024–32.
10. Wilde AAM, Ackerman MJ. Exercise extreme caution when calling rare genetic
variants novel arrhythmia syndrome susceptibility mutations. Heart Rhythm
2010;7:1883–5.
11. Pecini R, Cedergreen P, Theilade S, Haunsø S, Theilade J, Jensen GB. The preva-
lence and relevance of the Brugada-type electrocardiogram in the Danish general
population: data from the Copenhagen City Heart Study. Europace 2010;12:
982–6.
12. Tsuji H, Sato T, Morisaki K, Iwasaka T. Prognosis of subjects with Brugada-type
electrocardiogram in a population of middle-aged Japanese diagnosed during a
health examination. Am J Cardiol 2008;102:584–7.
13. Veltmann C, Schimpf R, Echternach C, Eckardt L, Kuschyk J, Streitner F et al. A
prospective study on spontaneous fluctuations between diagnostic and non-
diagnostic ECGs in Brugada syndrome: implications for correct phenotyping
and risk stratification. Eur Heart J 2006;27:2544–52.
14. Sinner MF, Pfeufer A, Perz S, Schulze-Bahr E, Monnig G, Eckardt L et al. Spontan-
eous Brugada electrocardiogram patterns are rare in the German general popu-
lation: results from the KORA study. Europace 2009;11:1338–44.
15. Gallagher MM, Forleo GB, Behr ER, Magliano G, De Luca L, Morgia V et al. Preva-
lence and significance of Brugada-type ECG in 12,012 apparently healthy
European subjects. Int J Cardiol 2008;130:44–8.
16. Hermida J-S, Lemoine J-L, Aoun FB, Jarry G, Rey J-L, Quiret J-C. Prevalence of the
Brugada syndrome in an apparently healthy population. Am J Cardiol 2000;86:
91–4.
17. Letsas KP, Gavrielatos G, Efremidis M, Kounas SP, Filippatos GS, Sideris A et al.
Prevalence of Brugada sign in a Greek tertiary hospital population. Europace
2007;9:1077–80.
18. Benito B, Brugada R, Brugada J, Brugada P. Brugada Syndrome. Prog Cardiovasc Dis
2008;51:1–22.
19. Yokokawa M, Noda T, Okamura H, Satomi K, Suyama K, Kurita T et al. Compari-
son of long-term follow-up of electrocardiographic features in Brugada syndrome
between the SCN5A-positive probands and the SCN5A-negative probands. Am J
Cardiol 2007;100:649–55.
20. Hong K, Brugada J, Oliva A, Berruezo-Sanchez A, Potenza D, Pollevick GD et al.
Value of electrocardiographic parameters and ajmaline test in the diagnosis of
Brugada syndrome caused by SCN5A mutations. Circulation 2004;110:3023–7.
21. Smits JPP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA et al. Genotype-
phenotype relationship in Brugada syndrome: electrocardiographic features differ-
entiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll
Cardiol 2002;40:350–6.
22. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gerard F et al. Outcome
after implantation of a cardioverter-defibrillator in patients with Brugada syn-
drome: a multicenter study. Circulation 2006;114:2317–24.
23. Rosso R, Glick A, Glikson M, Wagshal A, Swissa M, Rosenhek S et al. Outcome
after implantation of cardioverter defribrillator in patients with Brugada syn-
drome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J 2008;10:435–9.
24. Giustetto C, Drago S, Demarchi PG, Dalmasso P, Bianchi F, Masi AS et al. Risk
stratification of the patients with Brugada type electrocardiogram: a community-
based prospective study. Europace 2009;11:507–13.
25. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of indivi-
duals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophy-
siol 2006;17:577–83.
26. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM et al. Drugs
and Brugada syndrome patients: review of the literature, recommendations, and
an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335–41.
27. Raju H, Papadakis M, Govindan M, Bastiaenen R, Chandra N, O’Sullivan A et al.
Low prevalence of risk markers in cases of sudden death due to Brugada syn-
drome: relevance to risk stratification in Brugada syndrome. J Am Coll Cardiol
2011;57:2340–5.
28. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL et al.
Nationwide study of sudden cardiac death in persons aged 1–35 years. Eur
Heart J 2011;32:983–90.
29. van der Werf C, Hofman N, Tan HL, van Dessel PF, Alders M, van der Wal AC
et al. Diagnostic yield in sudden unexplained death and aborted cardiac arrest in
the young: the experience of a tertiary referral center in The Netherlands. Heart
Rhythm 2010;7:1383–9.
30. Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, Tome Esteban MT
et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable
heart disease in the majority of families. Eur Heart J 2008;29:1670–80.
Brugada syndrome in Denmark 1029
by guest on January 16, 2017
D
ow
nloaded from
 
